2026 Biocompatibility Updates: How to Plan Your Safety Assessment

With significant updates to global biocompatibility standards anticipated around 2026, medical device manufacturers must strategically re-evaluate their biological safety assessment plans to ensure ongoing compliance and prevent submission delays. The core of this evolution is a definitive shift away from a simple checklist of tests and toward a comprehensive, risk-based framework. A proactive approach is no longer optional; it is essential for navigating the changing regulatory landscape. This modern approach requires a deep understanding of a device's materials, manufacturing processes, and intended clinical use. The foundation of a successful biological evaluation is the Biological Evaluation Plan (BEP), a living document that outlines the entire safety assessment strategy. It begins with the systematic characterization of all patient-contacting materials, moves to a rigorous risk analysis, and culminates in a justified testing plan that leverages existing data to minimize unnecessary testing. For manufacturers, this means planning must start now to build the necessary data and rationale to support their device submissions in the coming years. ### Key Points * **Risk-Based Framework is Paramount:** Future compliance hinges on a holistic biological risk assessment as outlined in a comprehensive Biological Evaluation Plan (BEP), moving beyond a simple "check-the-box" approach to testing. * **Comprehensive Material Characterization is the Foundation:** A thorough understanding and documentation of every patient-contacting material, processing aid, colorant, and sterilization residual is the non-negotiable first step. * **Justification Can Reduce Animal Testing:** Evolving standards increasingly emphasize using robust scientific rationales, particularly chemical characterization data (Extractables & Leachables), to justify waiving certain biological endpoint tests. * **The Biological Evaluation Report (BER) Tells the Story:** The BER is the final narrative document that synthesizes all material data, risk assessments, testing results, and justifications into a cohesive safety argument for regulators. * **Proactive Planning is Essential:** Waiting for standards to be finalized is a recipe for delay. Manufacturers should begin implementing a risk-based framework and gathering necessary material data immediately. * **Early Regulatory Engagement De-Risks Submissions:** For devices involving novel materials, new manufacturing processes, or complex use cases, engaging with regulatory bodies like the FDA via the Q-Submission program is critical for aligning on the evaluation strategy before committing significant resources. ## The Shift Towards a Holistic Biological Risk Assessment Historically, biocompatibility was often treated as a pre-defined set of tests to be completed based on the device category and contact duration. However, global regulators, including the FDA, have increasingly adopted the principles of the ISO 10993 series of standards, which champion a risk-based approach. This shift requires manufacturers to act as investigators, not just test administrators. The central idea is that biological safety is not proven merely by passing a battery of tests but by demonstrating a thorough understanding of the device and its potential interactions with the human body. This holistic evaluation considers the complete life cycle, from raw material sourcing to post-sterilization residuals. A successful strategy results in a robust Biological Evaluation Report (BER) that doesn't just present data but tells a compelling and scientifically sound story about why the device is safe for its intended use. This approach is more scientifically rigorous and aligns with the global ethical push to reduce, refine, and replace animal testing (the "3Rs") whenever possible. ## Step-by-Step Framework for a Modern Biological Evaluation Plan (BEP) A well-structured Biological Evaluation Plan (BEP) is the roadmap for the entire safety assessment. It should be developed early in the product development process and updated as new information becomes available. ### Step 1: Comprehensive Device and Material Characterization This is the foundational stage where every component and process is scrutinized. Insufficient characterization is a common reason for regulatory deficiencies. * **Identify All Patient-Contacting Materials:** Create a detailed list of every single material that directly or indirectly contacts the patient. This includes not only primary components but also adhesives, coatings, inks, and manufacturing aids. * **Document Chemical Composition:** Obtain detailed compositional information from suppliers. Vague descriptions like "medical-grade polymer" are insufficient. The documentation should specify chemical names, CAS numbers, and proportions. * **Analyze Manufacturing Processes:** Map every manufacturing step—such as molding, machining, cleaning, and sterilization—and identify any substances used that could leave residues on the final device (e.g., mold release agents, cleaning solvents, ethylene oxide residuals). * **Perform Chemical Characterization:** For many devices, especially those with prolonged or permanent patient contact, analytical chemistry testing for Extractables and Leachables (E&L) is essential. This data provides a chemical fingerprint of the device and identifies substances that could potentially leach into the body. ### Step 2: Categorization of Device and Nature of Body Contact Using the information from Step 1, the device must be categorized according to established standards (e.g., ISO 10993-1). * **Device Category:** * **Surface-contacting:** Devices that contact skin, mucosal membranes, or breached surfaces (e.g., bandages, electrodes). * **Externally communicating:** Devices that contact internal tissues but remain outside the vascular system (e.g., catheters, dental fillings). * **Implantable:** Devices placed largely or entirely within the body (e.g., stents, orthopedic implants, pacemakers). * **Contact Duration:** * **Limited (A):** ≤ 24 hours * **Prolonged (B):** > 24 hours to 30 days * **Permanent (C):** > 30 days This categorization determines the initial set of biological endpoints that must be considered for the risk assessment. ### Step 3: Identification of Biological Risks and Potential Endpoints Based on the device category and material characterization, a comprehensive risk assessment is performed to identify all potential biological hazards. The goal is to evaluate which endpoints are relevant to the specific device. Common endpoints include: * Cytotoxicity * Sensitization * Irritation or Intracutaneous Reactivity * Systemic Toxicity (Acute, Subacute, Subchronic, and Chronic) * Genotoxicity * Hemocompatibility (for blood-contacting devices) * Implantation Effects * Carcinogenicity ### Step 4: Data Gap Analysis and Justified Testing Strategy With the relevant endpoints identified, the next step is to determine if sufficient data already exists to address them. * **Review Existing Information:** Collate all available data, including literature on the known safety of the materials, clinical history of use in other legally marketed devices, and any existing test data from suppliers. * **Identify the Gaps:** Compare the required endpoints with the existing data. Any endpoint not adequately addressed by current information represents a data gap. * **Develop a Testing Plan:** Create a plan to generate data *only for the identified gaps*. A key part of the modern approach is providing a strong scientific rationale for any standard tests that are being omitted. For example, if extensive clinical history shows a material is not a sensitizer, a new sensitization test may not be necessary, provided a strong justification is documented. ## Scenarios: Applying the Risk-Based Framework ### Scenario 1: A Low-Risk, Surface-Contacting Device * **Device Example:** A Class II wearable diagnostic sensor with skin-contacting silicone adhesive. Contact is for up to 72 hours (Prolonged). * **Assessment Focus:** The primary risks are related to direct skin contact. The biological endpoints of concern are **cytotoxicity, irritation, and sensitization**. Systemic toxicity is a very low risk due to the nature and duration of contact. * **Strategy:** 1. **Characterization:** Confirm the exact formulation of the silicone and any additives. Obtain a history of safe use for this specific material from the supplier. 2. **Gap Analysis:** If the material is well-established in legally marketed devices for similar uses, existing data may cover all endpoints. If it is a new formulation, data gaps for the "big three" (cytotoxicity, irritation, sensitization) will likely exist. 3. **Testing:** Conduct in vitro cytotoxicity testing and standard irritation and sensitization tests if required. 4. **BER Narrative:** The Biological Evaluation Report would summarize the material information, justify the focus on skin-contact endpoints, present the test results, and conclude the device is safe. ### Scenario 2: A High-Risk, Permanent Implant * **Device Example:** A novel, drug-eluting peripheral stent made with a new biodegradable polymer. * **Assessment Focus:** As a permanent implant in direct contact with blood and tissue, the risk profile is extensive. All endpoints, including **long-term systemic toxicity, genotoxicity, hemocompatibility, and implantation effects**, must be thoroughly evaluated. The degradation products of the new polymer are also a key concern. * **Strategy:** 1. **Characterization:** This is the most critical phase. An exhaustive E&L study is required to identify all potential leachables from the polymer and the drug. Degradation studies must be performed to understand how the device breaks down over time. 2. **Gap Analysis:** Given the novel polymer, significant data gaps will exist for nearly all long-term endpoints. 3. **Testing:** A comprehensive testing battery will be needed. This will likely include in vitro tests (cytotoxicity, genotoxicity, hemocompatibility) and in vivo studies to assess local tissue response (implantation) and long-term systemic effects. A toxicological risk assessment of the E&L data is critical to evaluate the safety of identified chemicals. 4. **BER Narrative:** The BER will be a complex document integrating E&L data, the toxicological risk assessment, all biocompatibility test results, and a detailed justification for the overall safety conclusion. ## Strategic Considerations and the Role of Q-Submission For devices with novel materials, new sterilization methods, or a complex risk profile like the stent in Scenario 2, early and transparent communication with the FDA is a powerful de-risking tool. The Q-Submission program allows manufacturers to present their proposed Biological Evaluation Plan and testing rationale to the agency for feedback *before* expensive and time-consuming tests are initiated. Submitting a well-reasoned BEP through the Q-Submission process can help gain alignment on: * The adequacy of the chemical characterization plan. * The justification for omitting certain biological tests. * The design of any proposed animal studies. * The overall biological safety evaluation strategy. Gaining this feedback early can prevent significant delays and costly rework during the final marketing submission review. ## Finding and Comparing Biocompatibility Testing Services Providers Choosing the right laboratory partner is crucial for executing a successful biological evaluation. When selecting a provider for biocompatibility testing, manufacturers should look for a partner, not just a testing facility. Key criteria for evaluation include: * **Accreditation and Compliance:** The lab must be compliant with Good Laboratory Practice (GLP) as required under 21 CFR Part 58 for studies supporting FDA submissions. ISO/IEC 17025 accreditation is also a strong indicator of quality. * **Technical Expertise:** The provider should have experienced toxicologists and chemists on staff who understand the nuances of the ISO 10993 standards and FDA guidance. They should be able to help design test plans and interpret complex data, especially from E&L studies. * **Experience with Similar Devices:** A lab with a track record of testing similar device types will be more familiar with the likely regulatory questions and potential challenges. * **Communication and Support:** A good partner provides clear communication, regular updates, and is available to discuss results and strategy. To find qualified vetted providers [click here](https://cruxi.ai/regulatory-directories/biocompatibility_testing) and request quotes for free. ## Key FDA References * **FDA Guidance on the Use of International Standard ISO 10993-1:** The primary guidance document outlining the agency's current thinking on biological evaluation of medical devices. * **FDA's Q-Submission Program Guidance:** Provides instructions on how to request feedback from the FDA on regulatory and testing strategies prior to a formal marketing submission. * **21 CFR Part 58 - Good Laboratory Practice for Nonclinical Laboratory Studies:** The regulation that governs the conduct of nonclinical safety studies, including many biocompatibility tests. This article is for general educational purposes only and is not legal, medical, or regulatory advice. For device-specific questions, sponsors should consult qualified experts and consider engaging FDA via the Q-Submission program. --- *This answer was AI-assisted and reviewed for accuracy by Lo H. Khamis.*